New York State Common Retirement Fund Sells 28,572 Shares of Guardant Health, Inc. $GH

New York State Common Retirement Fund decreased its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 27.2% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 76,283 shares of the company’s stock after selling 28,572 shares during the period. New York State Common Retirement Fund’s holdings in Guardant Health were worth $4,766,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. IFP Advisors Inc grew its holdings in Guardant Health by 120.1% during the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company’s stock worth $33,000 after acquiring an additional 334 shares during the period. Allworth Financial LP boosted its position in shares of Guardant Health by 358.4% in the 2nd quarter. Allworth Financial LP now owns 706 shares of the company’s stock worth $37,000 after purchasing an additional 552 shares during the last quarter. Sound Income Strategies LLC acquired a new stake in shares of Guardant Health during the third quarter worth $38,000. FNY Investment Advisers LLC bought a new stake in Guardant Health in the second quarter valued at about $62,000. Finally, SBI Securities Co. Ltd. lifted its stake in Guardant Health by 99.4% in the second quarter. SBI Securities Co. Ltd. now owns 1,366 shares of the company’s stock valued at $71,000 after buying an additional 681 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Trading Up 3.5%

Shares of NASDAQ GH opened at $101.85 on Friday. The company has a fifty day moving average price of $106.38 and a 200 day moving average price of $81.68. The firm has a market cap of $12.84 billion, a PE ratio of -31.73 and a beta of 1.63. Guardant Health, Inc. has a 1-year low of $34.88 and a 1-year high of $120.74.

Insider Activity at Guardant Health

In related news, CEO Helmy Eltoukhy sold 90,565 shares of the stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $103.82, for a total transaction of $9,402,458.30. Following the completion of the transaction, the chief executive officer directly owned 2,047,143 shares in the company, valued at approximately $212,534,386.26. This trade represents a 4.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Chris Freeman sold 31,452 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $103.07, for a total value of $3,241,757.64. Following the completion of the sale, the insider owned 25,987 shares in the company, valued at $2,678,480.09. The trade was a 54.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 434,627 shares of company stock valued at $45,592,052 over the last ninety days. Company insiders own 6.10% of the company’s stock.

Analyst Ratings Changes

GH has been the subject of several analyst reports. Evercore set a $105.00 target price on Guardant Health and gave the stock an “in-line” rating in a research report on Monday, January 5th. TD Cowen restated a “buy” rating on shares of Guardant Health in a report on Wednesday, January 7th. UBS Group reiterated a “buy” rating and issued a $175.00 target price on shares of Guardant Health in a report on Friday, January 30th. Citigroup lifted their price target on shares of Guardant Health from $100.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Finally, Barclays upped their price objective on shares of Guardant Health from $85.00 to $120.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Twenty-one analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $106.86.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.